UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies Summary of changes.
作者信息
Kokorovic Andrea, So Alan I, Serag Hosam, French Christopher, Hamilton Robert J, Izard Jason P, Nayak Jasmir G, Pouliot Frédéric, Saad Fred, Shayegan Bobby, Aprikian Armen, Rendon Ricardo A
机构信息
Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada.
出版信息
Can Urol Assoc J. 2022 Aug;16(8):243-244. doi: 10.5489/cuaj.8007.
Abstract
摘要
相似文献
1
UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies Summary of changes.更新 - 加拿大泌尿外科协会雄激素剥夺治疗指南：不良事件及管理策略 更改摘要
Can Urol Assoc J. 2022 Aug;16(8):243-244. doi: 10.5489/cuaj.8007.
2
UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.更新——加拿大泌尿外科协会雄激素剥夺治疗指南：不良事件与管理策略
Can Urol Assoc J. 2022 Aug;16(8):E416-E431. doi: 10.5489/cuaj.8054.
3
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary.加拿大泌尿外科协会雄激素剥夺治疗指南：不良事件与管理策略——执行摘要
Can Urol Assoc J. 2021 Jun;15(6):159-161. doi: 10.5489/cuaj.7357.
4
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.加拿大泌尿外科协会雄激素剥夺治疗指南：不良事件及管理策略
Can Urol Assoc J. 2021 Jun;15(6):E307-E322. doi: 10.5489/cuaj.7355.
5
2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Summary of changes.2022年更新：加拿大泌尿外科学会-加拿大泌尿肿瘤学组指南：转移性去势初治和去势敏感性前列腺癌 变更摘要
Can Urol Assoc J. 2022 Dec;16(12):389-391. doi: 10.5489/cuaj.8159.
6
Qualitative Review of Clinical Guidelines for Medical and Surgical Management of Urolithiasis: Consensus and Controversy 2020.2020 年尿石症医学和外科治疗临床指南的定性评价：共识与争议
J Urol. 2021 Apr;205(4):999-1008. doi: 10.1097/JU.0000000000001478. Epub 2020 Dec 7.
7
8
UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.更新 - 加拿大泌尿外科学会指南：肾结石的评估与药物治疗
Can Urol Assoc J. 2022 Jun;16(6):175-188. doi: 10.5489/cuaj.7872.
9
Management of the side effects of androgen deprivation therapy in men with prostate cancer.前列腺癌男性患者雄激素剥夺治疗副作用的管理
Expert Opin Pharmacother. 2008 Nov;9(16):2829-41. doi: 10.1517/14656566.9.16.2829.
10
UPDATE - 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) castration-resistant prostate cancer (CRPC) guideline: What has changed since 2019?更新 - 2021年加拿大泌尿外科协会（CUA）-加拿大泌尿肿瘤学组（CUOG）去势抵抗性前列腺癌（CRPC）指南：自2019年以来有哪些变化？
Can Urol Assoc J. 2021 Feb;15(2):11-12. doi: 10.5489/cuaj.7160.
引用本文的文献
1
2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update).2025年加拿大泌尿外科学会-加拿大泌尿肿瘤学组指南：转移性去势初治和去势敏感性前列腺癌（更新版）
Can Urol Assoc J. 2025 May;19(5):E142-E152. doi: 10.5489/cuaj.9240.
2
Cardiovascular Risk in Prostate Cancer: State-of-the-Art Review.前列腺癌中的心血管风险：最新综述
JACC CardioOncol. 2024 Nov 19;6(6):835-846. doi: 10.1016/j.jaccao.2024.09.012. eCollection 2024 Dec.
3
[Androgen Receptor Signaling Inhibitors and Cardiovascular Events in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis].雄激素受体信号抑制剂与晚期前列腺癌心血管事件：系统评价与荟萃分析
Urologie. 2024 Dec;63(12):1276-1280. doi: 10.1007/s00120-024-02464-7. Epub 2024 Nov 8.
4
[Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].[雄激素剥夺疗法与前列腺癌患者的心血管疾病发病率：一篇叙述性综述]
Urologie. 2024 Mar;63(3):262-268. doi: 10.1007/s00120-023-02222-1. Epub 2023 Oct 24.
本文引用的文献
1
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.前列腺癌患者中地加瑞克与亮丙瑞林的心血管安全性：PRONOUNCE 随机试验的主要结果。
Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30.
2
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.加拿大泌尿外科协会雄激素剥夺治疗指南：不良事件及管理策略
Can Urol Assoc J. 2021 Jun;15(6):E307-E322. doi: 10.5489/cuaj.7355.
3
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.口服瑞戈非尼在晚期前列腺癌中的雄激素剥夺治疗。
N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.
Zotero 插件